Alemtuzumab induction in kidney transplantation.

Edmund Huang, Yong W. Cho, Tariq Shah, Alice Peng, Rick Hayashi, Suphamai Bunnapradist

Research output: Contribution to journalArticle

Abstract

The use of alemtuzumab for induction therapy is increasing. 7.6% of antibody induction recipients in 2003 and 9.3% of induction recipients in 2004 received alemtuzumab. Antibody induction, especially T-cell depleting agents, Thymoglobulin and alemtuzumab are very effective in preventing early acute rejection in the initial hospitalization for both deceased and living donor transplants. However, when examining the effect of antibody induction on acute rejection after the initial hospitalization during the first year, alemtuzumab induction was associated with increased odds of acute rejection in deceased donor transplants compared to no antibody induction, IL-2RA, and Thymoglobulin. There was no difference in acute rejection during the first year after initial hospitalization in living donor transplants among all 4 induction groups. Despite lower acute rejection rates with alemtuzumab induction, no difference in graft survival was observed compared to no antibody induction, IL-2RA, and Thymoglobulin over 24 months. We conclude that alemtuzumab is an effective induction agent in kidney transplantation. However, further studies are needed to assess its long-term efficacy and to establish the optimal immunosuppressive regimen that should be maintained when alemtuzumab is used as an induction agent.

Original languageEnglish (US)
Pages (from-to)343-354
Number of pages12
JournalClinical transplants
StatePublished - 2005
Externally publishedYes

Fingerprint

Kidney Transplantation
Antibodies
Hospitalization
Living Donors
Transplants
Graft Survival
Immunosuppressive Agents
alemtuzumab
Tissue Donors
T-Lymphocytes
thymoglobulin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Huang, E., Cho, Y. W., Shah, T., Peng, A., Hayashi, R., & Bunnapradist, S. (2005). Alemtuzumab induction in kidney transplantation. Clinical transplants, 343-354.

Alemtuzumab induction in kidney transplantation. / Huang, Edmund; Cho, Yong W.; Shah, Tariq; Peng, Alice; Hayashi, Rick; Bunnapradist, Suphamai.

In: Clinical transplants, 2005, p. 343-354.

Research output: Contribution to journalArticle

Huang, E, Cho, YW, Shah, T, Peng, A, Hayashi, R & Bunnapradist, S 2005, 'Alemtuzumab induction in kidney transplantation.', Clinical transplants, pp. 343-354.
Huang E, Cho YW, Shah T, Peng A, Hayashi R, Bunnapradist S. Alemtuzumab induction in kidney transplantation. Clinical transplants. 2005;343-354.
Huang, Edmund ; Cho, Yong W. ; Shah, Tariq ; Peng, Alice ; Hayashi, Rick ; Bunnapradist, Suphamai. / Alemtuzumab induction in kidney transplantation. In: Clinical transplants. 2005 ; pp. 343-354.
@article{e40fea181ed84bb3879510e4b37442b4,
title = "Alemtuzumab induction in kidney transplantation.",
abstract = "The use of alemtuzumab for induction therapy is increasing. 7.6{\%} of antibody induction recipients in 2003 and 9.3{\%} of induction recipients in 2004 received alemtuzumab. Antibody induction, especially T-cell depleting agents, Thymoglobulin and alemtuzumab are very effective in preventing early acute rejection in the initial hospitalization for both deceased and living donor transplants. However, when examining the effect of antibody induction on acute rejection after the initial hospitalization during the first year, alemtuzumab induction was associated with increased odds of acute rejection in deceased donor transplants compared to no antibody induction, IL-2RA, and Thymoglobulin. There was no difference in acute rejection during the first year after initial hospitalization in living donor transplants among all 4 induction groups. Despite lower acute rejection rates with alemtuzumab induction, no difference in graft survival was observed compared to no antibody induction, IL-2RA, and Thymoglobulin over 24 months. We conclude that alemtuzumab is an effective induction agent in kidney transplantation. However, further studies are needed to assess its long-term efficacy and to establish the optimal immunosuppressive regimen that should be maintained when alemtuzumab is used as an induction agent.",
author = "Edmund Huang and Cho, {Yong W.} and Tariq Shah and Alice Peng and Rick Hayashi and Suphamai Bunnapradist",
year = "2005",
language = "English (US)",
pages = "343--354",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - Alemtuzumab induction in kidney transplantation.

AU - Huang, Edmund

AU - Cho, Yong W.

AU - Shah, Tariq

AU - Peng, Alice

AU - Hayashi, Rick

AU - Bunnapradist, Suphamai

PY - 2005

Y1 - 2005

N2 - The use of alemtuzumab for induction therapy is increasing. 7.6% of antibody induction recipients in 2003 and 9.3% of induction recipients in 2004 received alemtuzumab. Antibody induction, especially T-cell depleting agents, Thymoglobulin and alemtuzumab are very effective in preventing early acute rejection in the initial hospitalization for both deceased and living donor transplants. However, when examining the effect of antibody induction on acute rejection after the initial hospitalization during the first year, alemtuzumab induction was associated with increased odds of acute rejection in deceased donor transplants compared to no antibody induction, IL-2RA, and Thymoglobulin. There was no difference in acute rejection during the first year after initial hospitalization in living donor transplants among all 4 induction groups. Despite lower acute rejection rates with alemtuzumab induction, no difference in graft survival was observed compared to no antibody induction, IL-2RA, and Thymoglobulin over 24 months. We conclude that alemtuzumab is an effective induction agent in kidney transplantation. However, further studies are needed to assess its long-term efficacy and to establish the optimal immunosuppressive regimen that should be maintained when alemtuzumab is used as an induction agent.

AB - The use of alemtuzumab for induction therapy is increasing. 7.6% of antibody induction recipients in 2003 and 9.3% of induction recipients in 2004 received alemtuzumab. Antibody induction, especially T-cell depleting agents, Thymoglobulin and alemtuzumab are very effective in preventing early acute rejection in the initial hospitalization for both deceased and living donor transplants. However, when examining the effect of antibody induction on acute rejection after the initial hospitalization during the first year, alemtuzumab induction was associated with increased odds of acute rejection in deceased donor transplants compared to no antibody induction, IL-2RA, and Thymoglobulin. There was no difference in acute rejection during the first year after initial hospitalization in living donor transplants among all 4 induction groups. Despite lower acute rejection rates with alemtuzumab induction, no difference in graft survival was observed compared to no antibody induction, IL-2RA, and Thymoglobulin over 24 months. We conclude that alemtuzumab is an effective induction agent in kidney transplantation. However, further studies are needed to assess its long-term efficacy and to establish the optimal immunosuppressive regimen that should be maintained when alemtuzumab is used as an induction agent.

UR - http://www.scopus.com/inward/record.url?scp=34249718461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249718461&partnerID=8YFLogxK

M3 - Article

SP - 343

EP - 354

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -